1,684 Shares in Rapport Therapeutics (NASDAQ:RAPP) Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,684 shares of the company’s stock, valued at approximately $34,000.

Other large investors have also modified their holdings of the company. TD Asset Management Inc acquired a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at about $2,361,000. Johnson & Johnson purchased a new position in Rapport Therapeutics during the second quarter worth approximately $58,105,000. Sofinnova Investments Inc. acquired a new stake in Rapport Therapeutics in the second quarter valued at approximately $45,393,000. Davidson Kempner Capital Management LP purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $229,000. Finally, ARCH Venture Management LLC acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth approximately $86,730,000.

Rapport Therapeutics Stock Performance

Shares of NASDAQ:RAPP opened at $17.86 on Friday. The company’s 50 day simple moving average is $23.05. Rapport Therapeutics has a 1 year low of $16.55 and a 1 year high of $29.74.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.